Immunogenicity - OmicsDI

Show results for

Unknown (13094)
Genomics (854)
Transcriptomics (496)
Proteomics (155)
Clinical (53)
Other (31)
Methylation profiling (13)
Models (2)
Genomic (2)
Metabolomics (1)

Organisms

Homo sapiens (339)
Mus musculus (266)
Macaca mulatta (13)
Rattus norvegicus (8)
synthetic construct (7)
Mycobacterium tuberculosis (4)
Sus scrofa (3)
blank sample (3)
Campylobacter jejuni (2)
Danio rerio (2)
Measles virus strain Schwarz (2)
Mycobacterium tuberculosis variant bovis BCG (1)
Mycobacterium tuberculosis variant bovis BCG str. Pasteur 1173P2 (1)
Japanese encephalitis virus (1)
Elephas maximus (1)
Porcine epidemic diarrhea virus (1)
Measles morbillivirus (1)
Coxiella burnetii (1)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
Komagataella phaffii (1)
dengue virus type 4 (1)
Chlorocebus aethiops (1)
Human immunodeficiency virus 1 (1)
Cavia porcellus (1)
Influenza A virus (1)
Macaca fascicularis (1)
Chlorocebus sabaeus (1)
Cricetulus griseus (1)
Rattus rattus (1)
Spirometra erinaceieuropaei (1)

Organisms

Homo sapiens (277)
Mus musculus (212)
Macaca mulatta (13)
Rattus norvegicus (4)
synthetic construct (4)
Sus scrofa (3)
Mycobacterium tuberculosis (3)
Salmonella enterica subsp. enterica serovar Enteritidis (2)
Severe acute respiratory syndrome coronavirus 2 (2)
Autographa californica multiple nucleopolyhedrovirus (1)
Orf virus (1)
Streptococcus anginosus subsp. whileyi MAS624 (1)
Streptococcus anginosus T5 (1)
Streptococcus constellatus subsp. pharyngis SK1060 = CCUG 46377 (1)
Streptococcus anginosus 1505 (1)
Legionella sp. (1)
Streptococcus intermedius SK54 = ATCC 27335 (1)
Streptococcus constellatus subsp. constellatus SK53 (1)
Streptococcus anginosus SK52 = DSM 20563 (1)
Elephas maximus (1)
Avibacterium paragallinarum (1)
Mycoplasmopsis synoviae (1)
Mycobacterium tuberculosis variant bovis BCG (1)
Komagataella phaffii (1)
Aegilops tauschii x Triticum turgidum (1)
Chlorocebus aethiops (1)
Sus scrofa scrofa (1)
Porcine epidemic diarrhea virus (1)
Mannheimia haemolytica (1)
Mycobacterium avium subsp. paratuberculosis (1)

Repository

ENA (787)
geo (525)
pride (107)
biostudies-arrayexpress (79)
MassIVE (26)
iProX (11)
EGA (10)
jPOST (3)
BioModels (2)
dbGaP (2)
EVA (1)
MetabolomicsWorkbench (1)

Tissue

Cell culture (26)
B cell (12)
Epithelial cell (9)
Dendritic cell (8)
Blood (7)
Permanent cell line cell (7)
Skin (6)
Blood cell (4)
Blood serum (4)
Fibroblast (4)
Blood plasma (3)
Lung (3)
Malignant cell (3)
Melanocyte (3)
Bone marrow (2)
Colon (2)
Hepatocyte (2)
Kidney (2)
Liver (2)
Macrophage (2)
Monocyte (2)
Ovary (2)
Peripheral blood mononuclear cell (2)
Bacterial cells (1)
B-lymphoblast cell line (1)
Breast (1)
Breast cancer cell (1)
Breast cancer cell line (1)
Cell suspension culture (1)
Central nervous system (1)

Disease

Colorectal Neoplasms (18)
Neoplasms (7)
Melanoma (5)
Carcinoma (4)
Breast cancer (4)
Influenza (4)
Malignant neoplasm of ovary (4)
Acute leukemia (3)
Chronic lymphocytic leukemia (3)
Crohn Disease (2)
Neoplasm Metastasis (2)
Adenocarcinoma (2)
Lung Neoplasms (2)
Simian immunodeficiency virus (1)
Adult both male and femal patients treated for colorectal cancer (1)
Selected Advanced Solid Tumors (1)
Colorectal cancer metastatic (1)
Non-squamous non-small cell lung cancer (1)
Neoplasms, Glandular and Epithelial (1)
Colorectal Cancer, Non-small cell lung cancer, Head and Neck Cancer, Esophageal Cancer, etc (1)
Digestive System Neoplasms (1)
Colorectal cancer, Gastric cancer, Esophageal cancer, Biliary tract cancer, Pancreatic cancer, and Other Solid cancer (1)
In patients with metastatic colorectal cancer (mCRC) (1)
Carcinoma, Renal Cell (1)
Carcinoma, Squamous Cell (1)
Inflammatory Bowel Diseases (1)
Pancreatic Neoplasms (1)
Tumour, metastised colorectal cancer (1)
Glioblastoma (1)
Stomach Neoplasms (1)

Technology Type

Mass Spectrometry (108)
Shotgun proteomics (35)
Data-dependent acquisition (26)
Bottom-up proteomics (21)
Affinity purification coupled with mass spectrometry proteomics (18)
Immunopeptidomics (13)
Gel-based experiment (6)
SWATH MS (4)
Top-down proteomics (4)
All-ion fragmentation (2)
Data-independent acquisition (2)
MSE (2)
ESI (1)
Glycoproteomics (1)
RNA mass spectrometry (1)
SRM/MRM (1)

Instrument Platform

Illumina HiSeq 2000 (5)
Illumina NovaSeq 6000 (4)
Orbitrap Eclipse (4)
Orbitrap Exploris 480 (4)
Q Exactive HF-X (4)
Orbitrap Fusion Lumos (3)
Q Exactive (3)
NextSeq 500 (2)
LTQ Orbitrap (2)
Q Exactive Plus (2)
TimsTOF Pro 2 (2)
Illumina HiSeq X (1)
Illumina HiSeq 1500 (1)
NextSeq 550 (1)
Illumina HiSeq 2500 (1)
- (1)
LTQ Orbitrap XL (1)
QTRAP 5500 (1)
QTRAP 6500+ (1)
Synapt MS (1)
TimsTOF Pro (1)
TripleTOF 6600 (1)

Publication Date

2024 (129)
2026 (125)
2025 (120)
2022 (79)
2023 (75)
2021 (39)
2020 (30)
2014 (26)
2019 (18)
2015 (17)
2012 (17)
2016 (16)
2018 (13)
2013 (10)
2017 (8)
2008 (7)
2010 (6)
2011 (5)
2009 (5)
2007 (2)

UNIPROT ID/AC

C4NUM1 (1)
A2RSY7 (1)
Q9ES17 (1)

First Public Date

2026 (144)
2024 (138)
2025 (118)
2023 (87)
2022 (87)
2021 (60)
2020 (36)
2014 (32)
2019 (20)
2018 (17)
2015 (17)
2017 (12)
2016 (10)
2013 (9)

Modelling Approach

Ordinary differential equation model (1)
Constraint-based model (1)

Study status

Completed (21)
Recruiting (15)
Active, not recruiting (6)
Not provided (6)
Ongoing (2)
Terminated (1)
Withdrawn (1)
Not yet recruiting (1)

Lab affiliation

Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Office B25A/04/94 Rue du Bugnon 25a, CH-1005 Lausanne (3)
Infection and Immunity Program, Biomedicine Discovery Institute & Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia (3)
Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia (2)
Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany (2)
International Institute of Molecular and Cell Biology, Laboratory of RNA-Protein Interactions - Dioscuri Centre, Warsaw, Poland (2)
1 Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands 2 Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, The Netherlands (1)
1 Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA (1)
1 German Cancer Consortium of Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 2 IIIrd Medical Department, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany 3 Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany (1)
1. Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Germany 3. Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Germany 4. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Germany (1)
1F, Bldg A, No.18 Science Park Road, Life Science Park, Changping District, Beijing 102206, P. R. China (1)
Biochemistry Department, Kavli Institute for Nanoscience Discovery, University of Oxford, UK (1)
Bioinformatics Solutions Inc., Waterloo, Ontario, Canada (1)
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584 CH Utrecht, The Netherlands (1)
Broad Institute (1)
Cancer Biology Department, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Cell Biology, Harvard Medical School, Boston, MA, USA. (1)
Cell Death Investigation and Therapy (CDIT) Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium (1)
Center for Regeneration and Aging,BGI-haangzhou (1)
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina (1)
Department of Biochemistry Center for Biomedical Mass Spectrometry Boston University School of Medicine (1)
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton 3800, Victoria, Australia (lab head) (1)
Department of Biochemistry and Molecular Biology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton 3800 Victoria, Australia. (1)
Department of Biochemistry and Molecular Biology, School of Medicine, Tulane University, New Orleans, Louisiana 70112 (1)
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, United States (1)
Department of Biological Engineering, Massachusetts Institute of Technology & Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (1)
Department of Biology, Washington University in St. Louis (1)
Department of Biomedical Sciences, University of Padova, Italy (1)
Department of Chemistry, National University of Singapore (1)
Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University，Shanghai，China (1)
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (1)
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA (1)

Keyword

Leucovorin (5)
Bevacizumab (5)
Ipilimumab (4)
Aflibercept (4)
Irinotecan (4)
Cetuximab (4)
Urothelial Cancer (3)
Renal Cell Cancer (3)
Gastroesophageal Junction Cancer (3)
Durvalumab (3)
Nivolumab (3)
Immunotherapy (3)
Fluorouracil (3)
Levoleucovorin (3)
Oxaliplatin (3)
Anti-TNF (2)
Obinutuzumab (2)
Immunogenicity (2)
Hepatocellular/Liver Cancer (2)
MSS (2)
Neoantigen cancer vaccine (2)
Head and neck squamous cell carcinoma (HNSCC) (2)
PD-1 (2)
CTLA-4 (2)
Safety (2)
Triple Negative Breast Cancer (2)
Adalimumab (2)
Atezolizumab (2)
Pembrolizumab (2)
Antibodies (2)

IsPrivate

False (2)

Model Flag

Non Kinetic (1)

Submitter Keywords

Immuno-oncology (1)

Classification

bacteria (22)
viruses (6)

Modification

2x(15)N labeled L-lysine (1)
4x(15)N labeled L-arginine (1)

Study type

Transcription profiling by array (55)
Interventional (50)
RNA-seq of coding RNA (12)
Comparative genomic hybridization by array (3)
Proteomic profiling by array (3)
Observational (2)
Human - High-throughput sequencing (1)
High-throughput sequencing (1)
Human - One-color microarray (1)
DNA-seq (1)
RNA-seq of coding RNA from single cells (1)
RNA-seq of total RNA (1)
Observational patient registry (1)

Release Date

2022 (1911)
2023 (1564)
2021 (1406)
2025 (1388)
2024 (1308)
2020 (969)
2019 (691)
2018 (650)
2017 (588)
2016 (464)
2015 (432)
2014 (391)
2013 (286)
2012 (220)
2011 (173)
2026 (171)
2010 (145)
2009 (112)
2008 (82)
2007 (58)
2005 (34)
2006 (32)
2003 (26)
2004 (16)
2002 (16)
2001 (12)
1998 (10)
2000 (9)
1999 (9)

Location

United States (22)
China (12)
Spain (11)
South Korea (8)
Italy (8)
Netherlands (7)
Australia (7)
United Kingdom (7)
France (5)
Germany (4)
Belgium (4)
Japan (4)
New Zealand (3)
Denmark (3)
Canada (3)
Taiwan (2)
Ukraine (2)
Turkey (2)
Sweden (2)
Russia (2)
Poland (2)
Czechia (2)
South Africa (1)
Georgia (1)
Hong Kong (1)
Norway (1)
Estonia (1)
Singapore (1)
India (1)
Puerto Rico (1)

Previous page
1 / 1471
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 1471
Next page

Sort by:

Relevance

Page size

Enhanced systemic commensal E. coli immunogenicity through minor alteration of the metabolic profile

Not available

ORGANISM(S): Escherichia coli

ST002287 | MetabolomicsWorkbench

CD4+ Th immunogenicity of Ascaris spp.

Application of a reconstituted in vitro system to define the CD4+ Th immunogenicity of complex antigenic mixtures.

ORGANISM(S): Ascaris suum

2020-03-04 | PXD015924 | Pride

Cd4+ t cell epitope/ immunodominance/ immunogenicity/ mhcii antigen presentation/ ascaris spp./ pathogen

Elucidation of B-cell specific drug immunogenicity liabilities via a novel ex vivo assay

The appended raw files, csv files and other documents were deposited in the public domain in support for the publication "Elucidation of B-cell specific drug immunogenicity liabilities via a novel ex vivo assay" by Cary M Looney, Axel Ducret, Guido Steiner, Karen Dernick, Katharina Hartman, Michel S...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2025-02-19 | MSV000097151 | MassIVE

ExomeSeq Neoantigen Immunogenicity Landscapes

Immune checkpoint blockade (ICB) therapy is a cornerstone of oncologic treatment for patients with advanced stage non-small cell lung cancer (NSCLC) and other malignancies. Neoantigen immunoediting drives ICB efficacy, yet the fundamental physiochemical characteristics of neoantigens and how neoant...

EGAS00001007508 | EGA

RNASeq Neoantigen Immunogenicity Landscape

EGAS00001007509 | EGA

Development and qualification of a dendritic cell internalization assay contributing to the immunogenicity risk evaluation of biotherapeutics

The appended raw files, csv files and other documents were deposited into the public domain in support for the publication "Development and characterization of a dendritic cell internalization assay contributing to the immunogenicity risk evaluation of biotherapeutics" by Michel Siegel, Aman Padamse...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2024-08-12 | MSV000095578 | MassIVE

Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity

The appended raw files, csv files and other documents were deposited into the public domain in support for the publication "Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity" by Michel Siegel, Anna-Lena Bolender, Axel Ducret, Johannes Fraidling, Katha...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2024-08-26 | MSV000095695 | MassIVE

CD4+ Th immunogenicity of Ascaris spp.

Application of a reconstituted in vitro system to define the CD4+ Th immunogenicity of complex antigenic mixtures.

ORGANISM(S): Homo sapiens (Human) Ascaris suum

2020-03-04 | PXD015012 | Pride

The immunogenicity of human kidney organoids

PRJNA872155 | ENA

DC populations incubated with rAd5, rAd28, rAd35, TLR7/8-ligand, or unexposed

Recombinant adenovirus vectors (rAds) are being investigated as vaccine delivery vehicles in pre-clinical and clinical studies. rAds constructed from different serotypes differ in receptor usage, tropism, and ability to activate cells, aspects of which likely contribute to their different immunogeni...

ORGANISM(S): Homo sapiens

2012-07-10 | E-GEOD-37128 | biostudies-arrayexpress

Previous page
1 / 1471
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 1471
Next page

Sort by:

Relevance

Page size

14701 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Model Flag

Submitter Keywords

Classification

Modification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets